Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

[Content of C-reactive protein in patients in an acute period of a ruptured intracranial aneurysm].

Globa MV, Lisyanyi MI, Tsimeyko A, Litvak SO.

Klin Khir. 2015 Mar;(3):29-31. Ukrainian.

PMID:
26072539
2.

Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration.

Thierry S, Benleulmi MS, Sinzelle L, Thierry E, Calmels C, Chaignepain S, Waffo-Teguo P, Merillon JM, Budke B, Pasquet JM, Litvak S, Ciuffi A, Sung P, Connell P, Hauber I, Hauber J, Andreola ML, Delelis O, Parissi V.

Chem Biol. 2015 Jun 18;22(6):712-23. doi: 10.1016/j.chembiol.2015.04.020. Epub 2015 Jun 4.

3.

G-quadruplexes in viruses: function and potential therapeutic applications.

Métifiot M, Amrane S, Litvak S, Andreola ML.

Nucleic Acids Res. 2014 Nov 10;42(20):12352-66. doi: 10.1093/nar/gku999. Epub 2014 Oct 20. Review.

4.

Biochemical, cellular and molecular identification of DNA polymerase α in yeast mitochondria.

Lasserre JP, Plissonneau J, Velours C, Bonneu M, Litvak S, Laquel P, Castroviejo M.

Biochimie. 2013 Apr;95(4):759-71. doi: 10.1016/j.biochi.2012.11.003. Epub 2012 Nov 14.

PMID:
23160073
5.

Yeast and the AIDS virus: the odd couple.

Andréola ML, Litvak S.

J Biomed Biotechnol. 2012;2012:549020. doi: 10.1155/2012/549020. Epub 2012 Jun 17. Review.

6.

Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells.

Cosnefroy O, Tocco A, Lesbats P, Thierry S, Calmels C, Wiktorowicz T, Reigadas S, Kwon Y, De Cian A, Desfarges S, Bonot P, San Filippo J, Litvak S, Cam EL, Rethwilm A, Fleury H, Connell PP, Sung P, Delelis O, Andréola ML, Parissi V.

J Virol. 2012 Jan;86(1):513-26. doi: 10.1128/JVI.05425-11. Epub 2011 Oct 19.

7.

Cortical circuitry implementing graphical models.

Litvak S, Ullman S.

Neural Comput. 2009 Nov;21(11):3010-56. doi: 10.1162/neco.2009.05-08-783.

PMID:
19686065
8.

A new in vitro strand transfer assay for monitoring bacterial class 1 integron recombinase IntI1 activity.

Dubois V, Debreyer C, Litvak S, Quentin C, Parissi V.

PLoS One. 2007 Dec 19;2(12):e1315.

9.

Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery?

Métifiot M, Faure A, Guyonnet-Duperat V, Bellecave P, Litvak S, Ventura M, Andréola ML.

Oligonucleotides. 2007 Summer;17(2):151-65.

PMID:
17638520
10.

America's changing attitudes toward homosexuality, civil unions, and same-gender marriage: 1977-2004.

Avery A, Chase J, Johansson L, Litvak S, Montero D, Wydra M.

Soc Work. 2007 Jan;52(1):71-9.

PMID:
17388085
11.

Small-angle X-ray characterization of the nucleoprotein complexes resulting from DNA-induced oligomerization of HIV-1 integrase.

Baranova S, Tuzikov FV, Zakharova OD, Tuzikova NA, Calmels C, Litvak S, Tarrago-Litvak L, Parissi V, Nevinsky GA.

Nucleic Acids Res. 2007;35(3):975-87. Epub 2007 Jan 26.

12.

Chromosomal integration of LTR-flanked DNA in yeast expressing HIV-1 integrase: down regulation by RAD51.

Desfarges S, San Filippo J, Fournier M, Calmels C, Caumont-Sarcos A, Litvak S, Sung P, Parissi V.

Nucleic Acids Res. 2006;34(21):6215-24. Epub 2006 Nov 7.

13.

Targeting HIV-1 integrase with aptamers selected against the purified RNase H domain of HIV-1 RT.

Métifiot M, Leon O, Tarrago-Litvak L, Litvak S, Andréola ML.

Biochimie. 2005 Sep-Oct;87(9-10):911-9. Epub 2005 Apr 13.

PMID:
16164998
14.
15.

[Interaction of HIV-1 reverse transcriptase with new minor groove ligands and their conjugates with oligonucleotides].

Zakharova OD, Baranova SV, Riabinin VA, Siniakov AN, Iamkovoĭ VI, Tarrago-Litvak L, Litvak S, Nevinskiĭ GA.

Mol Biol (Mosk). 2005 May-Jun;39(3):477-87. Russian.

PMID:
15981577
16.

Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase.

Bessong PO, Obi CL, Andréola ML, Rojas LB, Pouységu L, Igumbor E, Meyer JJ, Quideau S, Litvak S.

J Ethnopharmacol. 2005 May 13;99(1):83-91.

PMID:
15848024
17.

HIV-1 integrase crosslinked oligomers are active in vitro.

Faure A, Calmels C, Desjobert C, Castroviejo M, Caumont-Sarcos A, Tarrago-Litvak L, Litvak S, Parissi V.

Nucleic Acids Res. 2005 Feb 17;33(3):977-86. Print 2005.

18.

Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.

Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.

Biochemistry. 2004 Oct 19;43(41):13097-105.

PMID:
15476403
19.

Selection of DNA aptamers that bind the RNA-dependent RNA polymerase of hepatitis C virus and inhibit viral RNA synthesis in vitro.

Bellecave P, Andreola ML, Ventura M, Tarrago-Litvak L, Litvak S, Astier-Gin T.

Oligonucleotides. 2003;13(6):455-63.

PMID:
15025912
20.

The lethal phenotype observed after HIV-1 integrase expression in yeast cells is related to DNA repair and recombination events.

Parissi V, Caumont A, de Soultrait VR, Desjobert C, Calmels C, Fournier M, Gourgue G, Bonneu M, Tarrago-Litvak L, Litvak S.

Gene. 2003 Dec 11;322:157-68.

PMID:
14644507
21.

An oligonucleotide complementary to the SL-B1 domain in the 3'-end of the minus-strand RNA of the hepatitis C virus inhibits in vitro initiation of RNA synthesis by the viral polymerase.

Reigadas S, Ventura M, Andreola ML, Michel J, Gryaznov S, Tarrago-Litvak L, Litvak S, Astier-Gin T.

Virology. 2003 Sep 15;314(1):206-20.

22.

Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase.

Bugreev DV, Baranova S, Zakharova OD, Parissi V, Desjobert C, Sottofattori E, Balbi A, Litvak S, Tarrago-Litvak L, Nevinsky GA.

Biochemistry. 2003 Aug 5;42(30):9235-47.

PMID:
12885259
23.

A promoter activity is present in the DNA sequence corresponding to the hepatitis C virus 5' UTR.

Dumas E, Staedel C, Colombat M, Reigadas S, Chabas S, Astier-Gin T, Cahour A, Litvak S, Ventura M.

Nucleic Acids Res. 2003 Feb 15;31(4):1275-81.

24.

DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents.

de Soultrait VR, Lozach PY, Altmeyer R, Tarrago-Litvak L, Litvak S, Andréola ML.

J Mol Biol. 2002 Nov 22;324(2):195-203.

PMID:
12441099
25.

HIV-1 integrase and RNase H activities as therapeutic targets.

Andréola ML, De Soultrait VR, Fournier M, Parissi V, Desjobert C, Litvak S.

Expert Opin Ther Targets. 2002 Aug;6(4):433-46. Review.

PMID:
12223059
26.

A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.

de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.

J Mol Biol. 2002 Apr 19;318(1):45-58.

PMID:
12054767
27.

Barriers to health and wellness from a disability perspective.

Kaplan D, Litvak S.

J Gend Specif Med. 2002 Mar-Apr;5(2):9-12. No abstract available.

PMID:
11974681
28.

Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.

Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S.

Curr Pharm Des. 2002;8(8):595-614. Review.

PMID:
11945161
29.

Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex.

Freund F, Boulmé F, Michel J, Ventura M, Moreau S, Litvak S.

Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):301-15.

PMID:
11763347
30.

HCV RNA-dependent RNA polymerase replicates in vitro the 3' terminal region of the minus-strand viral RNA more efficiently than the 3' terminal region of the plus RNA.

Reigadas S, Ventura M, Sarih-Cottin L, Castroviejo M, Litvak S, Astier-Gin T.

Eur J Biochem. 2001 Nov;268(22):5857-67.

31.

Functional interactions of human immunodeficiency virus type 1 integrase with human and yeast HSP60.

Parissi V, Calmels C, De Soultrait VR, Caumont A, Fournier M, Chaignepain S, Litvak S.

J Virol. 2001 Dec;75(23):11344-53.

32.

Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvak S, Nagle JW, Schiffmann R.

Clin Genet. 2001 Jul;60(1):46-51.

PMID:
11531969
33.

DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity.

Andreola ML, Pileur F, Calmels C, Ventura M, Tarrago-Litvak L, Toulmé JJ, Litvak S.

Biochemistry. 2001 Aug 28;40(34):10087-94.

PMID:
11513587
34.

Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex.

Freund F, Boulmé F, Litvak S, Tarrago-Litvak L.

Nucleic Acids Res. 2001 Jul 1;29(13):2757-65.

35.

Inhibition of HIV-1 integrase-catalysed reaction by new DNA minor groove ligands: the oligo-1,3-thiazolecarboxamide derivatives.

Ryabinin VA, Sinyakov AN, de Soultrait VR, Caumont A, Parissi V, Zakharova OD, Vasyutina EL, Yurchenko E, Bayandin R, Litvak S, Tarrago-Litvak L, Nevinsky GA.

Eur J Med Chem. 2000 Nov;35(11):989-1000.

PMID:
11137227
36.

Desmin splice variants causing cardiac and skeletal myopathy.

Park KY, Dalakas MC, Goebel HH, Ferrans VJ, Semino-Mora C, Litvak S, Takeda K, Goldfarb LG.

J Med Genet. 2000 Nov;37(11):851-7.

37.

Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing.

Bourara K, Litvak S, Araya A.

Science. 2000 Sep 1;289(5484):1564-6.

38.

Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides.

Andreola ML, Calmels C, Michel J, Toulmé JJ, Litvak S.

Eur J Biochem. 2000 Aug;267(16):5032-40.

39.

Sporadic cardiac and skeletal myopathy caused by a de novo desmin mutation.

Park KY, Dalakas MC, Semino-Mora C, Lee HS, Litvak S, Takeda K, Ferrans VJ, Goldfarb LG.

Clin Genet. 2000 Jun;57(6):423-9.

PMID:
10905661
40.

Synthesis and evaluation of oligo-1,3-thiazolecarboxamide derivatives as HIV-1 reverse transcriptase inhibitors.

Ryabinin VA, Zakharova OD, Yurchenko EY, Timofeeva OA, Martyanov IV, Tokarev AA, Belanov EF, Bormotov NI, Tarrago-Litvak L, Andreola ML, Litvak S, Nevinsky GA, Sinyakov AN.

Bioorg Med Chem. 2000 May;8(5):985-93.

PMID:
10882010
41.

Study of HIV-2 primer-template initiation complex using antisense oligonucleotides.

Boulmé F, Freund F, Gryaznov S, Nielsen PE, Tarrago-Litvak L, Litvak S.

Eur J Biochem. 2000 May;267(9):2803-11.

42.

Inactivation of the SNF5 transcription factor gene abolishes the lethal phenotype induced by the expression of HIV-1 integrase in yeast.

Parissi V, Caumont A, Richard de Soultrait V, Dupont CH, Pichuantes S, Litvak S.

Gene. 2000 Apr 18;247(1-2):129-36.

PMID:
10773452
43.

Selection of amino acid substitutions restoring activity of HIV-1 integrase mutated in its catalytic site using the yeast Saccharomyces cerevisiae.

Parissi V, Caumont AB, de Soultrait VR, Calmels C, Pichuantes S, Litvak S, Dupont CH.

J Mol Biol. 2000 Jan 28;295(4):755-65.

PMID:
10656788
44.

Interaction of oligonucleotides conjugated to substituted chromones and coumarins with HIV-1 reverse transcriptase.

Martyanov IV, Zakharova OD, Sottofattori E, Pyshnyi DV, Yurchenko EY, Babbi P, Mazzei M, Balbi A, Andreola ML, Litvak S, Tarrago-Litvak L, Nevinsky GA.

Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):473-80.

PMID:
10555155
45.

High affinity interaction of HIV-1 integrase with specific and non-specific single-stranded short oligonucleotides.

Caumont A, Jamieson G, de Soultrait VR, Parissi V, Fournier M, Zakharova OD, Bayandin R, Litvak S, Tarrago-Litvak L, Nevinsky GA.

FEBS Lett. 1999 Jul 16;455(1-2):154-8.

46.

Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions.

Ventura M, Tarrago-Litvak L, Dollé V, Nguyen CH, Legraverend M, Fleury HJ, Litvak S.

Arch Virol. 1999;144(3):513-23.

PMID:
10226617
47.

Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA.

Mestre B, Arzumanov A, Singh M, Boulmé F, Litvak S, Gait MJ.

Biochim Biophys Acta. 1999 Apr 14;1445(1):86-98.

PMID:
10209261
48.

Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease.

Lee HS, Sambuughin N, Cervenakova L, Chapman J, Pocchiari M, Litvak S, Qi HY, Budka H, del Ser T, Furukawa H, Brown P, Gajdusek DC, Long JC, Korczyn AD, Goldfarb LG.

Am J Hum Genet. 1999 Apr;64(4):1063-70.

49.

Cross-linking localization of a HIV-1 reverse transcriptase peptide involved in the binding of primer tRNALys3.

Dufour E, Reinbolt J, Castroviejo M, Ehresmann B, Litvak S, Tarrago-Litvak L, Andreola ML.

J Mol Biol. 1999 Jan 29;285(4):1339-46.

PMID:
9917377
50.

Interaction of tRNA-derivatives and oligonucleotide primers with AZT-resistant mutants of HIV-1 reverse transcriptase.

Zakharova OD, Suturina OA, Timofeeva OA, Gudima SO, Yamkovoi VI, Kochetkov SN, Fournier M, Tarrago-Litvak L, Litvak S, Nevinsky GA.

Bioorg Med Chem. 1998 Nov;6(11):2041-9.

PMID:
9881095

Supplemental Content

Loading ...
Support Center